IL-27 Blockade in Neonatal Sepsis

Evidence

Two primary studies examined IL-27 signaling in experimental neonatal sepsis. Both used newborn mice infected with K1-encapsulated Escherichia coli, so the evidence is preclinical and specific to one model. The older full-text study removed IL-27 receptor signaling genetically and investigated immune-cell movement. The newer abstract-level study neutralized the IL-27p28 subunit with an antibody, testing whether the genetic signal could be approached pharmacologically.

The 2026 study induced sepsis by subcutaneously inoculating neonatal mouse pups with K1-encapsulated E. coli. Pups given an IL-27p28 monoclonal antibody before infection had better bacterial clearance and gained more weight during infection than controls. In a separate post-infection experiment, researchers administered the antibody with an experimentally described subclinical gentamicin dose two hours after inoculation. Compared with gentamicin alone, the combination improved bacterial clearance and glucose homeostasis, lowered serum IL-6 and TNF-alpha, reduced vital-organ damage, and improved survival. These are outcomes reported in the PubMed abstract; the ingested source does not provide group sizes, effect magnitudes, antibody dose, randomization details, or full statistical results.

The 2025 study asked how absent IL-27 signaling might produce such changes. Four-day-old wild-type mice and mice lacking functional IL-27 receptor alpha were inoculated with E. coli O1:K1:H7. Most tissue, gene-expression, and cell-migration measurements were made 24 hours later. The experiments focused on CXCR2, a chemokine receptor involved in directing immune-cell movement toward chemical signals such as CXCL2.

During infection, spleens from receptor-deficient pups increased CXCR2 expression, whereas wild-type spleens reduced it. The pattern for the ligand differed: wild-type pups strongly increased CXCL2, while receptor-deficient pups showed a more moderate increase. Splenocytes from infected receptor-deficient pups also migrated more efficiently toward CXCL2 in a transwell assay than cells from infected wild-type pups.

Cell-separation experiments localized the largest difference to mononuclear cells rather than neutrophils. CXCR2 expression rose about 32-fold in splenic mononuclear cells from infected receptor-deficient pups relative to their uninfected controls, while wild-type mononuclear cells did not show a significant infection-linked change. Flow cytometry found a larger CXCR2-positive, Ly6C-high mononuclear population in infected receptor-deficient pups. Exposing isolated mononuclear cells to CXCL2 ex vivo produced more CXCR2 expression at the lower tested concentration and less at the higher concentration in cells from both genotypes, supporting an environmentally regulated rather than fixed cellular difference.

The receptor-deficient pups also had lower spleen bacterial burdens, better-preserved spleen architecture, serum AST values closer to uninfected controls, and better maintenance of weight and blood glucose than infected wild-type pups. Together, those measurements connect altered chemokine-receptor behavior with bacterial control and markers of tissue injury, but they do not prove that CXCR2 alone caused every improved outcome.

Analysis — Genetic and antibody evidence converge

The cross-study pattern is a progression from mechanism to intervention, not a clinical treatment result. Genetic loss of IL-27 receptor signaling was associated with preserved CXCR2 expression, stronger mononuclear-cell migration, lower bacterial burden, and less tissue injury. The newer antibody experiment independently changed IL-27 availability and reported better clearance and survival, including when paired with an antibiotic after infection. That convergence strengthens the inference that IL-27 signaling is functionally involved in this mouse model rather than merely correlated with severe infection.

A plausible analysis is that limiting IL-27 prevents an excessive chemokine environment from reducing CXCR2 responsiveness, allowing mononuclear cells to reach infected tissue while avoiding some inflammatory damage. The 2025 experiments support pieces of that pathway, but the 2026 abstract does not report CXCR2 measurements, so connecting antibody benefit to the same mechanism remains a hypothesis. The studies also came from a closely related experimental program and used the same narrow pathogen model. They therefore provide internal mechanistic consistency, not broad independent replication across laboratories, organisms, or human infants.

Limitations

Both studies used neonatal mice, not newborn patients. Subcutaneous inoculation with one K1-encapsulated E. coli strain cannot represent the varied organisms, infection routes, gestational ages, intensive-care exposures, and immune states involved in human neonatal sepsis. Lifelong absence of a receptor can also reshape immune development differently from short-term antibody neutralization.

The 2025 study used small groups for many experiments, sometimes three to five pups per condition, pooled spleens for some cell isolations, and concentrated measurements around 24 hours. Its authors did not identify the splenic source of CXCL2, did not perform a time course in blood and bone marrow, and could not establish that every CXCR2-positive, Ly6C-high cell had been newly recruited rather than already residing in tissue.

The 2026 source was available only as an abstract. Without full methods and results, the briefing cannot audit allocation, blinding, attrition, absolute survival, effect sizes, toxicity, or whether antibody and antibiotic effects were additive or interactive. Neither study establishes antibody pharmacology, immune consequences, developmental safety, or efficacy in human newborns. The findings define an emerging host-response research direction; they do not support neonatal treatment decisions.